Full Press Release Details
Dr. Michael A. Luther Joins Transgenomic's
OMAHA, Neb. (March 19, 2014)
-- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology,
and inherited diseases through diagnostic tests as well as clinical and research services, today announced the appointment of Michael
A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. His appointment
became effective March 13, 2014.
"Dr. Luther brings a unique combination
of scientific expertise, practical business experience, and effective leadership, and we are honored to welcome him to the Transgenomic
Board" said Rodney S. Markin, M.D., Ph.D., Chairman of Transgenomic. "We believe Michael's contributions will
be invaluable as we continue to implement our strategic growth initiatives and advance our molecular diagnostic tests in the personalized
medicine marketplace."
"I am excited to join the Transgenomic
Board during this period of strategic transformation," said Dr. Luther. "Molecular diagnostics will play an integral
role in the future of healthcare and Transgenomic is well-positioned to become a leader in personalized medicine. The Company has
cutting-edge technology platforms, deep technical expertise, and an excellent management team. I look forward to working with the
entire team and playing a role in the advancement of its portfolio of medically important genetic tests."
Dr. Luther brings over 25 years of business
experience to Transgenomic. He currently serves as Senior Vice President of Discovery and Development at Albany Molecular Research,
Inc. (AMRI), a publicly-traded, global pharma services organization that provides discovery, development, and manufacturing to
the biopharmaceutical industry. Dr. Luther joined AMRI from Charles River Laboratories where he served as Corporate Vice President
of Global Discovery Research Services. Before joining Charles River Laboratories, he was President and a member of the Board of
Directors of the David H. Murdock Research Institute. Previously, he held executive and managerial positions at Merck and GlaxoSmithkline.
Dr. Luther earned his Ph.D. in biochemistry
from the St. Louis University School of Medicine; an M.B.A. from Duke University, Fuqua School of Business; and a B.Sc. in biology
and chemistry from North Carolina State University. Dr. Luther has authored numerous scientific papers and has served on Boards
of Directors for both academic and industry trade organizations, including the Chagas Disease Foundation, and the College of Life
Sciences Research Foundation at North Carolina State University. He is also a Director for Islet Sciences.
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com)
is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases. The Company
has three complementary business units: Patient Testing, Biomarker Identification, and Genetic Assays and Platforms, which provide
specialized diagnostic tests, contract research services for drug development, and equipment, reagents and other consumables for
clinical and research applications in molecular testing and cytogenetics.
Forward-Looking Statements
Certain statements in this press release
constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform
Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially
different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements
include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances,
industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in
the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in
such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred
to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information
in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.
David Pitts, 212-600-1902
Donna Christian, 402-452-5416